Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airleaf
NCT05238675Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 2 trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Started Apr 2022; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT05238675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238675.